CORT: FDA Warned on Relacorilant – Shares Dive Again!

Company Overview

Corcept Therapeutics (NASDAQ: CORT) is a commercial-stage pharmaceutical company focused on cortisol modulation therapies. Its sole marketed drug, Korlym (mifepristone), treats Cushing’s syndrome (hypercortisolism) and has driven the company’s revenue growth (ir.corcept.com). Corcept has been developing relacorilant, a next-generation cortisol modulator, to expand its hypercortisolism franchise and into oncology. Management had ambitious targets – expressing confidence in growing its Cushing’s (hypercortisolism) business to $3–5 billion in annual revenue within 3–5 years (www.prnewswire.com) – largely hinging on relacorilant’s success. However, investor optimism was abruptly checked on December 31, 2025, when Corcept announced the FDA issued a Complete Response Letter (CRL) for relacorilant in hypercortisolism, indicating the agency “could not arrive at a favorable benefit-risk assessment… without additional evidence of effectiveness.” (www.prnewswire.com) The FDA’s rejection – essentially a delay/denial of approval – sent Corcept shares plunging ~50% (over $35 drop in price) in one day (www.prnewswire.com), erasing about $3.6 billion of market value. This is the second major blow to the stock in recent years, as shares had already dived in early 2024 after Corcept lost a patent dispute with Teva over Korlym (apnews.com), raising fears of generic competition. The latest FDA setback compounds concerns about Corcept’s future growth drivers.

Dividend Policy & Capital Allocation

Corcept does not pay any cash dividend, and has never declared regular dividends since inception. The company instead returns capital to shareholders via stock buybacks when excess cash allows. For example, in April 2023 Corcept repurchased 6.6 million shares (over 5% of shares outstanding) for $145.4 million (ir.corcept.com). This sizable buyback was funded by operating cash flows from Korlym sales – reflecting management’s confidence in the business. As a result of no dividends, Corcept’s current dividend yield is 0%. Traditional REIT metrics like AFFO/FFO are not applicable here; instead, investors focus on earnings and cash flow from product sales. Corcept’s operations have been profitable (e.g. $27.5 million net income in Q2 2023 (ir.corcept.com)) and generate cash, enabling it to self-fund R&D and occasional buybacks without relying on external financing. The lack of a dividend is typical for biotech companies prioritizing pipeline investment over shareholder payouts.

Leverage & Debt Maturities

Leverage is minimal for Corcept. The company carries little to no debt on its balance sheet – instead it has built a substantial cash reserve from retained earnings. As of March 31, 2025, Corcept held $570.8 million in cash and investments (www.marketscreener.com), providing a large net cash position. No significant loans or bond obligations are evident in recent filings, meaning no near-term debt maturities to service. This debt-free balance sheet greatly reduces financial risk: interest expense is negligible and liquidity is robust. In essence, Corcept’s ongoing Korlym profits have funded its growth, eliminating the need for leverage. The company’s interest coverage is therefore strong by default – with positive EBIT and no interest costs, coverage ratios are a non-issue. This conservative financial structure gives Corcept flexibility to withstand setbacks (like the FDA delay) without facing creditor pressure. It’s worth noting that Corcept’s ample cash could even be redeployed for strategic purposes (e.g. to support new trials or acquisitions) given the company’s changing outlook.

Valuation

Prior to the recent plunge, Corcept’s valuation had reflected high expectations for relacorilant. The stock reached all-time highs around $75 in late 2025 (www.marketbeat.com) ahead of the FDA decision, trading at elevated multiples. At that peak, the trailing P/E ratio was over 90× earnings (financhill.com) (indicative of modest current profits against a ~$7+ billion market cap), and even forward P/E was ~24× on optimistic 2025 profit forecasts (financhill.com). The price-to-sales also swelled given 2024 revenue was in the ~$600 million range. However, the dramatic ~50% share price collapse has brought valuations down to earth. At roughly $35/share after the CRL (about a $3.5 billion market cap) (www.prnewswire.com), Corcept now trades at roughly 3.5–4× its prior 2025 revenue guidance of $900–$950 million (www.marketscreener.com). By comparison, this sales multiple is in line with or lower than many profitable biotech peers, reflecting the newly uncertain growth outlook. The trailing P/E has likely compressed into the ~40–50× range after the drop (still high, due to heavy R&D suppressing net income), and if one assumes the company can achieve its pre-CRL 2025 earnings targets, the forward P/E would be near the high-teens. In sum, the market is now primarily valuing Corcept on its existing Korlym franchise and cash, assigning little credit to pipeline upside. The stock’s re-rating underscores a shift from a growth valuation to a more skeptical, asset-based valuation until confidence in new revenue streams is restored.

Risks and Red Flags

Corcept faces a number of heightened risks and red flags following recent events:

- Regulatory Setback & Pipeline Uncertainty: The FDA’s refusal to approve relacorilant for Cushing’s syndrome (via the CRL) is a major setback (www.prnewswire.com). Relacorilant was the lead pipeline candidate meant to drive growth and reduce reliance on Korlym (www.trefis.com). Now, its approval is delayed indefinitely pending additional trials or data. This raises doubts about Corcept’s overall pipeline quality and the viability of its cortisol modulation strategy beyond the first product. With no other late-stage candidates near approval, Corcept lacks a clear path to diversify revenue in the near term (www.trefis.com).

- Concentration & Generic Competition: Corcept’s reliance on one product (Korlym) is a key vulnerability. Korlym’s U.S. orphan exclusivity has expired, and patent defenses are weakening. In late 2023, Corcept lost a patent dispute to Teva regarding Korlym (apnews.com), which opens the door for a generic mifepristone to enter the market. While Corcept is likely appealing and may still have some patent arguments, a generic launch in the next 1–2 years is a real possibility. Generic competition could rapidly erode Korlym’s ~$400–500 million annual sales, slashing the company’s cash flow engine. This risk is amplified by existing brand-name competitors: Recordati’s Isturisa (osilodrostat) and Xeris’ Recorlev (levoketoconazole) were approved in 2020–2021 as alternative Cushing’s treatments, intensifying market competition. Notably, Recordati recently secured FDA approval to expand Isturisa’s label and now targets €550–650 million in peak sales for that drug (www.globenewswire.com) – a sign that Korlym’s market share is under threat. In short, market and pricing pressure on Corcept’s only product is a significant looming headwind.

- Legal and Governance Concerns: The sharp stock drop on the relacorilant news has prompted scrutiny of Corcept’s prior communications and governance. A shareholder rights law firm (Hagens Berman) is investigating whether Corcept misled investors about relacorilant’s efficacy and prospects (www.prnewswire.com). In the past, management had been extremely bullish on relacorilant (as noted, projecting multi-billion revenue potential) (www.prnewswire.com). If the FDA’s rejection implies management overlooked or downplayed issues with the Phase 3 data, there could be credibility damage or even legal repercussions. While such class-action probes are common after biotech setbacks – and do not always lead to findings of wrongdoing – it’s a red flag worth monitoring. Additionally, Corcept has faced controversy before; for example, some critics have accused the company of exploiting orphan drug loopholes and aggressive tactics to protect Korlym’s franchise (including the Teva patent fight and an antitrust lawsuit related to delaying generic entry). These issues highlight governance and ethical risks that investors should weigh alongside the clinical and commercial challenges.

- Execution Risk & Financial Impact: Even aside from the FDA outcome, drug development is inherently risky. Corcept must decide how to proceed with relacorilant for Cushing’s – conducting new costly trials with uncertain success – or potentially abandoning the indication. The company’s R&D spending will remain high as it pursues other programs (cortisol modulators in oncology, metabolism, etc.), pressuring margins. There is a risk that without relacorilant’s near-term boost, Corcept’s earnings could decline (especially if Korlym sales plateau or fall). Any future trial failures or regulatory hurdles in other indications (e.g. the ongoing Phase 2 trials in NASH and ALS, or the upcoming ovarian cancer NDA review) would compound the negative narrative. On the financial side, if Korlym revenues shrink faster than R&D and legal costs, Corcept could even swing to net losses in coming years. While the current cash reserve is a buffer, sustained setbacks could eventually strain the company’s ability to self-fund its pipeline.

In summary, Corcept’s investment case now carries substantial risks: product concentration, pipeline setbacks, competitive and legal challenges, and questions about management’s credibility. The “red flags” have increased, warranting a cautious outlook until the company can address or mitigate these issues.

Open Questions & Outlook

Looking ahead, several critical questions remain open about Corcept’s trajectory:

- What is the path forward for relacorilant in Cushing’s? Will the FDA require an entirely new Phase 3 trial to demonstrate efficacy, and how long might that take? Management expressed commitment to “find a way to get relacorilant to the patients it could help” and to meet with FDA “as soon as possible” to discuss next steps (www.prnewswire.com) (www.prnewswire.com). Investors will want clarity on whether Corcept can resubmit the drug (and on what timeline), or if this indication is on hold indefinitely. The outcome will determine if relacorilant’s potential $1+ billion market opportunity can eventually be realized, or if it’s effectively lost.

- Will the FDA approve relacorilant for ovarian cancer in 2026? Corcept has a second NDA filed: relacorilant plus nab-paclitaxel for platinum-resistant ovarian cancer, with a PDUFA decision date of July 11, 2026 (www.biospace.com). The Phase 3 data (ROSELLA trial) showed improved progression-free and overall survival in that setting (ir.corcept.com). This is a separate indication reviewed by oncology regulators, so the hypercortisolism CRL may not directly impact it. An approval here could provide a new revenue stream and a much-needed win. However, questions remain about the commercial potential – how large is the platinum-resistant ovarian cancer market and can Corcept successfully market an oncology drug? Moreover, any delay or rejection of this NDA would be a further blow to the pipeline. Investors are watching this FDA decision as a key catalyst in 2026.

- When and how will generic Korlym enter the market? After the patent litigation loss to Teva (apnews.com), it’s expected that generic competition is looming. The exact timing could hinge on appeals or settlements. If a generic mifepristone launches in 2025–2026, how steep will Korlym’s sales decline? Will Corcept respond by cutting price or focusing on niches? This is perhaps the biggest question for Corcept’s near-term financial outlook. The company’s 2025 revenue guidance of $900+ million (www.marketscreener.com) likely assumed no generic entry that year. A generic could cut that trajectory significantly, jeopardizing the company’s ability to fund R&D at current levels. Clarity on the legal resolution with Teva (or any licensing deal) will be crucial for modeling Corcept’s cash flows beyond 2025.

- Can Corcept’s cash cushion and business development fill the gap? With over half a billion in cash on hand (www.marketscreener.com), Corcept has resources to maneuver. Will management deploy this cash for M&A or in-licensing to diversify its portfolio now that internal efforts hit a roadblock? In 2024–25 the company refrained from big acquisitions, instead investing in its own pipeline and buying back stock. Going forward, investors may press Corcept to consider using its cash (and future free cash flow from Korlym while it lasts) to acquire revenue-generating assets or promising drug candidates to rebuild growth. How Corcept balances returning capital (via buybacks) versus reinvesting in new opportunities is an open question, especially if core earnings face erosion.

- What is the long-term outlook for Corcept’s cortisol modulation platform? Beyond relacorilant, Corcept is advancing other compounds (such as miricorilant in metabolism/NASH and trials in adrenal cancer, prostate cancer, and ALS) (www.marketbeat.com) (www.marketbeat.com). These programs are earlier-stage. Can any of them emerge as a significant therapy, or will Corcept need to radically refocus its R&D? The scientific premise – modulating cortisol to treat various conditions – is still intriguing, but recent events raise skepticism. Investors will be looking for clinical readouts (e.g. data from the Phase 2b NASH trial MONARCH (www.marketbeat.com)) to gauge if Corcept’s pipeline has hidden value or if the company is becoming a narrow one-drug story. If upcoming trial results are positive, they could restore some confidence; negative results would reinforce bear concerns.

In conclusion, Corcept Therapeutics is at a crossroads. The stock’s steep declines underscore the risks of a concentrated biotech model when key growth drivers falter. In the near term, preserving the cash cow (Korlym) and resolving the relacorilant situation are paramount. Longer-term, management must prove that Corcept can innovate beyond its first success. The company’s strong balance sheet and remaining pipeline shots provide some hope, but until the above questions are answered, many investors will remain on the sidelines. Corcept’s story has dramatically shifted from one of unchecked growth potential to one of rebuilding and risk management – making the next few quarters of updates from the FDA and the courts critical to watch (www.prnewswire.com) (www.prnewswire.com). The market will be looking for evidence that the “dive” in shares is an overreaction and not a reflection of permanently diminished prospects. Only clear progress on these open issues will determine if CORT can regain investor confidence or if further turbulence lies ahead.